pSivida Corp. Company Profile (NASDAQ:PSDV)

About pSivida Corp. (NASDAQ:PSDV)

pSivida Corp. logopSivida Corp. develops drug delivery products primarily for the treatment of chronic eye diseases. The Company operates through the biotechnology sector segment. The Company has developed three products for treatment of back-of-the-eye diseases, which include Medidur for posterior segment uveitis, its lead product candidate that is in pivotal Phase III clinical trials; ILUVIEN for diabetic macular edema (DME), its lead licensed product that is sold in the United States and European Union (EU) countries, and Retisert. Medidur is designed to treat chronic non-infectious uveitis affecting the posterior segment of the eye (posterior segment uveitis). ILUVIEN is an injectable micro-insert that provides treatment of DME from a single injection. Retisert is an implant that provides treatment of posterior segment uveitis. Its product development program is focused on utilizing its two technology platforms, Durasert and Tethadur, to deliver drugs and biologics to treat chronic diseases.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:PSDV
  • CUSIP: N/A
  • Web: www.psivida.com
Capitalization:
  • Market Cap: $42.51 million
  • Outstanding Shares: 39,268,000
Average Prices:
  • 50 Day Moving Avg: $1.39
  • 200 Day Moving Avg: $1.72
  • 52 Week Range: $1.05 - $4.07
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -1.93
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $7.14 million
  • Price / Sales: 5.94
  • Book Value: $0.35 per share
  • Price / Book: 3.09
Profitability:
  • EBIDTA: ($16,140,000.00)
  • Net Margins: -262.62%
  • Return on Equity: -119.87%
  • Return on Assets: -80.00%
Debt:
  • Current Ratio: 3.33%
  • Quick Ratio: 3.33%
Misc:
  • Average Volume: 713,323 shs.
  • Beta: 1.25
  • Short Ratio: 0.39
 
Frequently Asked Questions for pSivida Corp. (NASDAQ:PSDV)

What is pSivida Corp.'s stock symbol?

pSivida Corp. trades on the NASDAQ under the ticker symbol "PSDV."

How were pSivida Corp.'s earnings last quarter?

pSivida Corp. (NASDAQ:PSDV) posted its quarterly earnings data on Thursday, May, 4th. The company reported ($0.15) EPS for the quarter, meeting analysts' consensus estimates of ($0.15). The business had revenue of $0.59 million for the quarter, compared to analyst estimates of $0.36 million. pSivida Corp. had a negative return on equity of 119.87% and a negative net margin of 262.62%. View pSivida Corp.'s Earnings History.

When will pSivida Corp. make its next earnings announcement?

pSivida Corp. is scheduled to release their next quarterly earnings announcement on Monday, September, 11th 2017. View Earnings Estimates for pSivida Corp..

Where is pSivida Corp.'s stock going? Where will pSivida Corp.'s stock price be in 2017?

5 brokerages have issued 12-month price targets for pSivida Corp.'s shares. Their forecasts range from $5.00 to $13.00. On average, they expect pSivida Corp.'s share price to reach $8.60 in the next twelve months. View Analyst Ratings for pSivida Corp..

Who are some of pSivida Corp.'s key competitors?

Who are pSivida Corp.'s key executives?

pSivida Corp.'s management team includes the folowing people:

  • David J. Mazzo Ph.D., Independent Chairman of the Board
  • Nancy S. Lurker, President, Chief Executive Officer, Independent Director
  • Leonard S. Ross, Vice President - Finance, Principal Financial Officer
  • Debora A. Jorn, Executive Vice President - Corporate and Commercial Development
  • James J. Barry Ph.D., Independent Director
  • Jay S. Duker M.D., Independent Director
  • Douglas Evan Godshall M.B.A., Independent Director
  • Kristine Peterson, Independent Director
  • Michael W. Rogers, Independent Director

Who owns pSivida Corp. stock?

pSivida Corp.'s stock is owned by many different of retail and institutional investors. Top institutional investors include PFIZER INC (4.70%), Vanguard Group Inc. (2.80%), Bard Associates Inc. (0.23%), FineMark National Bank & Trust (0.18%), OxFORD Asset Management LLP (0.18%) and California Public Employees Retirement System (0.17%). Company insiders that own pSivida Corp. stock include Leonard S Ross, Nancy Lurker and Paul Ashton. View Institutional Ownership Trends for pSivida Corp..

Who sold pSivida Corp. stock? Who is selling pSivida Corp. stock?

pSivida Corp.'s stock was sold by a variety of institutional investors in the last quarter, including Vanguard Group Inc. and Bard Associates Inc.. View Insider Buying and Selling for pSivida Corp..

Who bought pSivida Corp. stock? Who is buying pSivida Corp. stock?

pSivida Corp.'s stock was purchased by a variety of institutional investors in the last quarter, including OxFORD Asset Management LLP. View Insider Buying and Selling for pSivida Corp..

How do I buy pSivida Corp. stock?

Shares of pSivida Corp. can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is pSivida Corp.'s stock price today?

One share of pSivida Corp. stock can currently be purchased for approximately $1.08.


MarketBeat Community Rating for pSivida Corp. (NASDAQ PSDV)
Community Ranking:  3.7 out of 5 (  )
Outperform Votes:  86 (Vote Outperform)
Underperform Votes:  29 (Vote Underperform)
Total Votes:  115
MarketBeat's community ratings are surveys of what our community members think about pSivida Corp. and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for pSivida Corp. (NASDAQ:PSDV) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 5 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $8.60 (696.30% upside)

Analysts' Ratings History for pSivida Corp. (NASDAQ:PSDV)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
7/11/2017HC WainwrightSet Price TargetBuy$5.00HighView Rating Details
6/14/2017Ladenburg Thalmann Financial ServicesSet Price TargetBuy$13.00MediumView Rating Details
6/14/2017Northland SecuritiesSet Price TargetBuy$10.00MediumView Rating Details
6/14/2017FBR & CoReiterated RatingBuyHighView Rating Details
5/30/2017Rodman & RenshawInitiated CoverageBuy$8.00HighView Rating Details
(Data available from 8/17/2015 forward)

Earnings

Earnings History for pSivida Corp. (NASDAQ:PSDV)
Earnings by Quarter for pSivida Corp. (NASDAQ:PSDV)
Earnings History by Quarter for pSivida Corp. (NASDAQ PSDV)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
9/11/2017($0.14)N/AView Earnings Details
5/4/2017Q3 2017($0.15)($0.15)$0.36 million$0.59 millionViewListenView Earnings Details
11/7/2016Q1($0.19)($0.21)$0.30 million$0.28 millionViewListenView Earnings Details
9/12/2016Q4($0.13)($0.19)$2.40 million$0.30 millionViewListenView Earnings Details
5/5/2016Q3($0.20)($0.15)$1.75 million$0.32 millionViewN/AView Earnings Details
11/5/2015Q116($0.15)($0.17)$0.50 million$0.47 millionViewN/AView Earnings Details
9/9/2015Q415($0.14)($0.17)$0.60 million$0.41 millionViewN/AView Earnings Details
5/8/2015Q315($0.13)($0.17)$0.33 millionViewN/AView Earnings Details
2/5/2015($0.13)($0.14)$0.52 millionViewN/AView Earnings Details
11/7/2014Q3 14($0.12)$0.67$25.30 millionViewN/AView Earnings Details
9/9/2014Q414($0.15)($0.15)$0.29 millionViewN/AView Earnings Details
5/13/2014Q314($0.15)($0.03)$0.55 million$2.00 millionViewN/AView Earnings Details
2/7/2014Q214($0.13)($0.13)$430.00 million$0.59 millionViewN/AView Earnings Details
11/12/2013Q1($0.14)ViewListenView Earnings Details
9/25/2013Q413($0.12)($0.17)$0.65 million$0.49 millionViewN/AView Earnings Details
2/6/2013Q2 2013($0.11)$0.63 million$0.59 millionViewListenView Earnings Details
11/8/2012Q113($0.10)($0.11)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for pSivida Corp. (NASDAQ:PSDV)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20171($0.19)($0.19)($0.19)
Q3 20171($0.17)($0.17)($0.17)
Q4 20171($0.12)($0.12)($0.12)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for pSivida Corp. (NASDAQ:PSDV)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for pSivida Corp. (NASDAQ:PSDV)
Insider Ownership Percentage: 2.59%
Institutional Ownership Percentage: 20.13%
Insider Trades by Quarter for pSivida Corp. (NASDAQ:PSDV)
Institutional Ownership by Quarter for pSivida Corp. (NASDAQ:PSDV)
Insider Trades by Quarter for pSivida Corp. (NASDAQ:PSDV)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/14/2017Nancy LurkerInsiderBuy56,700$1.76$99,792.00View SEC Filing  
1/4/2016Leonard S. RossVPSell5,000$4.70$23,500.00View SEC Filing  
12/22/2015Leonard S. RossVPSell33,950$5.39$182,990.50View SEC Filing  
12/22/2015Paul AshtonCEOSell120,000$5.39$646,800.00View SEC Filing  
10/1/2014Paul AshtonCEOSell10,000$4.27$42,700.00View SEC Filing  
9/2/2014Paul AshtonCEOSell10,000$4.78$47,800.00View SEC Filing  
8/1/2014Paul AshtonCEOSell10,000$4.37$43,700.00View SEC Filing  
7/1/2014Paul AshtonCEOSell10,000$4.32$43,200.00View SEC Filing  
6/19/2014Paul AshtonCEOSell7,000$4.00$28,000.00View SEC Filing  
6/17/2014Lori FreedmanVPSell7,900$4.00$31,600.00View SEC Filing  
6/17/2014Paul AshtonCEOSell7,700$4.00$30,800.00View SEC Filing  
6/13/2014Lori FreedmanVPSell11,700$4.02$47,034.00View SEC Filing  
6/13/2014Paul AshtonCEOSell11,800$4.02$47,436.00View SEC Filing  
10/1/2012Paul HopperDirectorBuy10,000$1.68$16,800.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for pSivida Corp. (NASDAQ:PSDV)
Latest Headlines for pSivida Corp. (NASDAQ:PSDV)
Source:
DateHeadline
seekingalpha.com logopSivida (PSDV) Presents At Canaccord Genuity 37th Annual Growth Conference - Slideshow
seekingalpha.com - August 13 at 4:07 AM
globenewswire.com logopSivida to Present at Canaccord Genuity Growth Conference on August 10, 2017 - GlobeNewswire (press release)
globenewswire.com - August 3 at 7:05 AM
finance.yahoo.com logopSivida to Present at Canaccord Genuity Growth Conference on August 10, 2017
finance.yahoo.com - August 2 at 6:49 AM
americanbankingnews.com logopSivida Corp. (NASDAQ:PSDV) Expected to Announce Quarterly Sales of $520,000.00
www.americanbankingnews.com - August 1 at 8:05 AM
americanbankingnews.com logo Brokerages Expect pSivida Corp. (PSDV) to Post -$0.14 Earnings Per Share
www.americanbankingnews.com - July 30 at 2:09 PM
globenewswire.com logoLeading Retinal Specialists to Highlight pSivida's Durasert for Treatment of Posterior Segment Uveitis at ... - GlobeNewswire (press release)
globenewswire.com - July 18 at 7:36 AM
finance.yahoo.com logoLeading Retinal Specialists to Highlight pSivida’s Durasert for Treatment of Posterior Segment Uveitis at Prestigious Ophthalmology Conferences
finance.yahoo.com - July 18 at 7:36 AM
seekingalpha.com logopSivida: Spec Biotech With Major Buy Signals - Seeking Alpha
seekingalpha.com - July 15 at 7:42 AM
americanbankingnews.com logo$530,000.00 in Sales Expected for pSivida Corp. (NASDAQ:PSDV) This Quarter
www.americanbankingnews.com - July 8 at 10:30 AM
americanbankingnews.com logo Analysts Expect pSivida Corp. (NASDAQ:PSDV) to Post -$0.14 Earnings Per Share
www.americanbankingnews.com - July 6 at 10:30 AM
globenewswire.com logopSivida Enhances Board of Directors with Election of Veteran Healthcare Executive Kristine Peterson - GlobeNewswire (press release)
globenewswire.com - June 28 at 8:59 AM
finance.yahoo.com logopSivida Enhances Board of Directors with Election of Veteran Healthcare Executive Kristine Peterson
finance.yahoo.com - June 28 at 8:59 AM
americanbankingnews.com logopSivida Corp. (PSDV) PT Set at $8.00 by HC Wainwright
www.americanbankingnews.com - June 25 at 11:06 PM
streetinsider.com logopSivida (PSDV) Submits MAA for Approval of Durasert Three-year Treatment for Posterior Segment Uveitis in EU
www.streetinsider.com - June 23 at 8:02 PM
streetinsider.com logopSivida (PSDV) Submits MAA for Approval of Durasert Three-year Treatment for Posterior Segment Uveitis in EU - StreetInsider.com
www.streetinsider.com - June 22 at 7:57 AM
finance.yahoo.com logoWatertown’s pSivida files for European approval of treatment to prevent blindness
finance.yahoo.com - June 22 at 7:57 AM
finance.yahoo.com logopSivida Submits Marketing Authorization Application (MAA) for Approval of Durasert™ Three-year Treatment for Posterior Segment Uveitis in the European Union
finance.yahoo.com - June 22 at 7:57 AM
seekingalpha.com logoWhy PSivida's Recent Trial Results Are Still Stellar Despite The Downward Movement - Seeking Alpha
seekingalpha.com - June 16 at 9:09 AM
americanbankingnews.com logopSivida Corp. (PSDV) PT Set at $10.00 by Northland Securities
www.americanbankingnews.com - June 15 at 10:48 PM
americanbankingnews.com logoHC Wainwright Analysts Give pSivida Corp. (PSDV) a $8.00 Price Target
www.americanbankingnews.com - June 15 at 10:46 PM
americanbankingnews.com logoLadenburg Thalmann Financial Services Analysts Give pSivida Corp. (PSDV) a $13.00 Price Target
www.americanbankingnews.com - June 15 at 2:32 PM
americanbankingnews.com logoFBR & Co Reaffirms Buy Rating for pSivida Corp. (PSDV)
www.americanbankingnews.com - June 14 at 9:40 PM
americanbankingnews.com logoInsider Buying: pSivida Corp. (PSDV) Insider Buys 56,700 Shares of Stock
www.americanbankingnews.com - June 14 at 8:18 PM
americanbankingnews.com logopSivida Corp. (PSDV) Expected to Post Quarterly Sales of $530,000.00
www.americanbankingnews.com - June 14 at 12:45 PM
streetinsider.com logopSivida's (PSDV) Three-year Treatment for Posterior Segment Uveitis Achieves Primary Efficacy Endpoint in Second Phase 3 Study
www.streetinsider.com - June 14 at 8:44 AM
nasdaq.com logoBUZZ-US STOCKS ON THE MOVE-Cleantech, Psivida, Sears Canada, Essendant - Nasdaq
www.nasdaq.com - June 14 at 12:27 AM
rttnews.com logoPSivida: Durasert Second Phase 3 Trial Meets Primary Efficacy Goal
www.rttnews.com - June 13 at 7:26 PM
nasdaq.com logoBUZZ-US STOCKS ON THE MOVE-Apple, pSivida, Magnegas - Nasdaq
www.nasdaq.com - June 13 at 10:17 AM
streetinsider.com logopSivida's (PSDV) Three-year Treatment for Posterior Segment Uveitis Achieves Primary Efficacy Endpoint in Second ... - StreetInsider.com
www.streetinsider.com - June 13 at 10:17 AM
finance.yahoo.com logopSivida’s Durasert™ Three-year Treatment for Posterior Segment Uveitis Successfully Achieves Primary Efficacy Endpoint in Second Phase 3 Study
finance.yahoo.com - June 13 at 10:17 AM
feeds.benzinga.com logopSivida's Durasert™ Three-year Treatment for Posterior Segment Uveitis Successfully Achieves Primary Efficacy Endpoint in Second Phase 3 Study
feeds.benzinga.com - June 13 at 7:23 AM
americanbankingnews.com logo Brokerages Expect pSivida Corp. (PSDV) to Announce -$0.14 Earnings Per Share
www.americanbankingnews.com - June 12 at 10:24 AM
seekingalpha.com logopSivida Undervalued With Final Phase III Durasert Data Imminent
seekingalpha.com - June 9 at 7:34 PM
streetinsider.com logoPre-Open Movers 05/30: (PTGX) (ATW) (XTLY) Higher; (AMBA) (WLL) (BWLD) Lower (more...)
www.streetinsider.com - May 30 at 7:01 PM
americanbankingnews.com logopSivida Corp. (PSDV) Earns Buy Rating from Analysts at Rodman & Renshaw
www.americanbankingnews.com - May 30 at 6:58 PM
americanbankingnews.com logopSivida Corp.'s (PSDV) "Buy" Rating Reaffirmed at HC Wainwright
www.americanbankingnews.com - May 30 at 7:55 AM
finance.yahoo.com logoETFs with exposure to pSivida Corp. : May 22, 2017
finance.yahoo.com - May 22 at 6:29 PM
seekingalpha.com logoAn Eye On Ophthalmology: Analyzing pSivida's Upcoming Clinical Trial
seekingalpha.com - May 17 at 7:17 PM
americanbankingnews.com logo Analysts Expect pSivida Corp. (PSDV) Will Announce Quarterly Sales of $550,000.00
www.americanbankingnews.com - May 17 at 9:12 AM
americanbankingnews.com logoBrokers Set Expectations for pSivida Corp.'s FY2017 Earnings (PSDV)
www.americanbankingnews.com - May 17 at 8:44 AM
americanbankingnews.com logoFBR & Co Weighs in on pSivida Corp.'s FY2021 Earnings (PSDV)
www.americanbankingnews.com - May 16 at 1:48 PM
americanbankingnews.com logoZacks: Analysts Anticipate pSivida Corp. (PSDV) to Announce -$0.17 EPS
www.americanbankingnews.com - May 15 at 10:28 PM
americanbankingnews.com logopSivida Corp.'s (PSDV) "Outperform" Rating Reiterated at FBR & Co
www.americanbankingnews.com - May 15 at 12:42 PM
finance.yahoo.com logoETFs with exposure to pSivida Corp. : May 11, 2017
finance.yahoo.com - May 11 at 7:48 PM
streetinsider.com logopSivida (PSDV) Announces Positive Durasert 3-Year Treatment Data - StreetInsider.com
www.streetinsider.com - May 10 at 11:26 AM
finance.yahoo.com logopSivida Corp. :PSDV-US: Earnings Analysis: Q3, 2017 By the Numbers : May 10, 2017
finance.yahoo.com - May 10 at 11:26 AM
streetinsider.com logopSivida (PSDV) Announces Positive Durasert 3-Year Treatment Data
www.streetinsider.com - May 8 at 11:56 AM
finance.yahoo.com logoDurasert™ Three-year Treatment for Posterior Segment Uveitis Significantly Reduces Recurrences Through 12 Months
finance.yahoo.com - May 8 at 11:56 AM
americanbankingnews.com logopSivida Corp. (PSDV) Issues Quarterly Earnings Results
www.americanbankingnews.com - May 5 at 8:08 PM
finance.yahoo.com logoEdited Transcript of PSDV earnings conference call or presentation 4-May-17 8:30pm GMT
finance.yahoo.com - May 5 at 7:35 PM

Social

Chart

pSivida Corp. (PSDV) Chart for Thursday, August, 17, 2017

This page was last updated on 8/17/2017 by MarketBeat.com Staff